Jul. 20 at 6:33 PM
$PFE
A lot of investors are calling Pfizer a high-yield bargain, but I think it's worth looking beyond the 7%+ dividend.
The bull case is obvious: historically low valuation, attractive yield, and a long dividend history. But the cash flow picture tells a different story.
By the end of 2025, Pfizer's free cash flow payout ratio was above 107%, a level that has remained elevated for several years. At the same time, 2026 guidance points to flat or slightly lower revenue, and the company has yet to repurchase shares this year despite trading at depressed valuation multiples.
If earnings and free cash flow don't recover, maintaining and growing the dividend becomes much harder. High yield alone isn't an investment thesis. Cash flow is what matters.
